ClinicalTrials.gg
CompletedNCT04559464CONVERTUpdated Nov 4, 2024

Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

An interventional study of AeriSeal and Zephyr Valves in Emphysema, COPD and Severe Emphysema, sponsored by Pulmonx Corporation. Completed at 14 sites in 7 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Pulmonx Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Emphysema with a site in United Kingdom — 4 open to participants now, 7 under way, none of them phase 3. Emphysema · United Kingdom.

Enrollment
13th of 35
102 · median 73
Started
2020
the only one that year
No phase
14 of 46
2 open now
Registered
37th of 46
by date
Lead sponsor
3 of 46
Pulmonx Corporation

Among the 46 studies in Emphysema with a site in United Kingdom, this one is the 13th largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2020, is one of 14 with no phase, and was the 37th registered.

Emphysema

382 studies on the registry are indexed under Emphysema; 58 are open to participants now.

Browse Emphysema studies →

Open to participants now

4 of the 46 studies in Emphysema with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 49 Emphysema studies recruiting now, 27 (55%) set no upper age limit and 8 (16%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Emphysema with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a prospective, open-label, multi-center, single-arm study to be conducted at up to 20 investigational sites. The Study plans to enroll up to 140 subjects with severe emphysema and collateral ventilation in the target lobe. This protocol is designed to evaluate the utility of the AeriSeal System to occlude collateral air channels in a target lung lobe with collateral ventilation (CV) and convert the target lung lobe to having little to no collateral ventilation. Subjects can then receive Zephyr Valves to achieve atelectasis in the targeted lobe, once AeriSeal has converted the CV+ lobe to a CV- one. Therefore, the study will have two Stages:

  • Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System; conversion of the CV+ target lobe to CV-. Conversion of collateral ventilation will be evaluated by Chartis after 45 days. In the case of unsuccessful conversion, a second treatment of AeriSeal may be attempted, provided that the total application volume from both the initial and the repeat treatments does not exceed 40 mL in up to three (3) segments.

Clinical Assessments post-AeriSeal will be conducted at 28 and 45 days after first treatment and repeated after the second treatment, if applicable. For the purpose of protocol follow-up, the Day 45 post-AeriSeal final treatment will equal Day 0 for Stage 2.

  • Stage 2 will include successfully converted subjects; CV+ to CV- conversion in Stage 1. Converted CV- target lobes will follow standard of care and receive CE marked Zephyr Endobronchial valves per the Zephyr IFU to perform bronchoscopic lung volume reduction (BLVR).

Clinical assessments will be conducted at 45 Days, 3-months, 6-months, and 12-months post-Zephyr Valve procedure.

Read the detailed description

Severe emphysema subjects will be consented using an Ethics Committee approved Informed Consent Form (ICF) for baseline evaluations. Subjects with ≥ 50% lobar emphysema destruction (evaluated quantitatively by using percentage lung volume occupied by low-attenuation regions/voxels) and identified as potentially having collateral ventilation, with fissure completeness ≥ 80% from the Quantitative Computed Tomography (QCT) report (CV status later to be confirmed by Chartis assessment at Visit 2) will undergo additional QCT assessment for the feasibility of directing AeriSeal to the appropriate segment to seal the anatomical defect. Subjects in whom this is considered feasible will be enrolled.

Enrolled subjects will undergo a bronchoscopy procedure during which the presence of collateral ventilation will be confirmed using the Chartis Pulmonary Assessment System (Pulmonx Corporation) and if confirmed, will undergo AeriSeal treatment in the segment(s) feeding the collateral channel. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments. Subjects will be hospitalized for a minimum of two (2) nights for observation and discharged if stable. Following discharge, subjects will be contacted daily for at least 7 days via telephone to assess status and solicit any Adverse Events.

Subjects that have little to no collateral ventilation at the initial bronchoscopy, as assessed by the Chartis Pulmonary Assessment System, will be exited from the study.

Six (6) weeks following the AeriSeal treatment, subjects will undergo a second bronchoscopy procedure for assessment of collateral ventilation status of the AeriSeal treated lobe with Chartis. If the Chartis assessment shows presence of collateral ventilation (CV+) at the lobar level, Chartis will be used to assess collateral ventilation at the segmental level to identify the segment with open collaterals. A second treatment with AeriSeal will be considered, provided the total delivered volume inclusive of the original treatment does not exceed 40 mL per subject. The post-procedure follow-up assessments for the second treatment will be repeated as after the initial treatment.

If the Chartis assessment determines little to no collateral ventilation (CV-) in the AeriSeal treated lobe, the lobe will be treated with Zephyr Valves as per the standard valve placement procedure. Subject will be hospitalized for a minimum of three (3) nights post-valve placement procedure and discharged with follow-up in accordance with this protocol, which includes standard post-valve placement follow-up.

Subjects who do not convert from CV+ to CV- status will continue to be observed for safety through 12 months following AeriSeal treatment or re-treatment, whichever is later.

The primary AeriSeal endpoint is the percentage of study subjects that are successfully converted from a positive collateral ventilation (CV+) status in the treated lobe to having little to no collateral ventilation (CV-) in the treated lobe.

Following the procedure for Zephyr Valve placement, subjects will be required to undergo Pulmonary Rehabilitation as per the local/national guidelines of each participating institution; at least 20 supervised sessions. A High Resolution Computed Tomography (HRCT) will be performed at 45-days post-Zephyr Valve procedure to determine Treated Lobe Volume Reduction (TLVR). Lung function will be assessed by measuring post-bronchodilator FEV1. A valve adjustment procedure will be considered if there is lack of TLVR (≤ 350 mL reduction from the pre-valve assessment) following evaluation of the High-resolution computed tomography (HRCT) to determine which valve needs to be replaced or addition of a new valve at a previously missed airway. Subjects will also be evaluated at 3-months, 6-months, and 12 months following Zephyr Valve placement.

03

Conditions studied

  • Emphysema
  • COPD
  • Severe Emphysema

Keywords

  • Bronchoscopic lung volume reduction
  • Zephyr Valves
  • AeriSeal
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is willing and able to provide and to participate in the study.
  2. Subject is ≥ 40 and ≤ 75 years of age at the time Informed Consent signature.
  3. Subject has at least one lobe with ≥ 50% emphysema destruction (at -910 HU) as determined by QCT.
  4. Subject has a diagnosis of homogenous or heterogeneous emphysema, confirmed by HRCT scan. Heterogeneous emphysema defined as ≥ 15% difference (at -910 HU) in emphysema destruction score of adjacent lobes by HRCT.
  5. Subject has a gap in the interlobar fissure that corresponds to one or more segments as determined by QCT.
  6. Subject has dyspnea with a mMRC Dyspnea score ≥ 2.
  7. Subject has a Six-Minute Walk Distance ≥ 250 meters.
  8. Subject has post-bronchodilator ≥ 15% predicted and ≤ 50% predicted.
  9. Subject has post-bronchodilator Total Lung Capacity ≥ 100% predicted.
  10. Subject has post-bronchodilator Residual Volume ≥ 150% predicted if heterogeneous emphysema and ≥ 200% predicted if homogeneous emphysema.
  11. Subject has stopped smoking for at least eight (8) weeks prior to Screening visit as confirmed by carboxyhemoglobin or cotinine levels.
  12. Subject has received preventive vaccinations against potential respiratory infections consistent with local recommendations or policy.

Exclusion criteria

Exclusion Criteria:

  1. Subject has severe bullous emphysema where bulla is ≥ 1/3 of the total lung volume.
  2. Subject has had prior lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung transplantation, prior airway stent placement, prior ipsilateral pleurodesis, or prior endobronchial lung volume reduction therapy of any type.
  3. Subject has evidence of active respiratory infection.
  4. Subject has an ongoing exacerbation or bronchospasm.
  5. Subject has a known allergy to the device components:

    1. Polyether block amide - PEBAX®
    2. Polyvinyl Alcohol
    3. Glutaraldehyde
    4. Nitinol (nickel-titanium) or its constituent metals (nickel or titanium)
    5. Silicone
  6. Subject requires invasive ventilatory support (NOTE: The use of continuous Positive Airway Pressure (CPAP) and BiPAP devices for Sleep Apnea is permitted).
  7. Subject has post-bronchodilator Diffusion Capacity (DLCO) \< 20% predicted.
  8. Subject cannot tolerate or relevant antibiotics.
  9. Subject has other relevant comorbidities as judged by the Investigator or is deconditioned and cannot tolerate the stress of post-treatment inflammatory response.
  10. Subject has had three (3) or more COPD exacerbations requiring hospitalization during the year prior to signature.
  11. Subject has severe gas exchange abnormalities as defined by any one of the following (test conducted at rest on room air as tolerated, or on up to 4 L/min supplemental O2):

    1. PaCO2 ≥ 55 mm Hg (7.3 kPa)
    2. PaO2 \< 45 mm Hg (6.0 kPa)
    3. SpO2 \< 90%
  12. Subject has uncontrolled pulmonary hypertension, defined as peak pulmonary systolic pressure > 45 mm Hg on echocardiogram or right heart catheterization.
  13. Subject use of systemic steroids > 20 mg/day prednisolone or equivalent within 4 weeks of Informed Consent signature.
  14. Subject use of agents within four (4) weeks of Informed Consent signature.
  15. Subject whose use heparins and oral anticoagulants (e.g., warfarin, dicumarol) cannot be discontinued according to local pre-procedural protocols. Note: antiplatelet drugs including aspirin and clopidogrel are permitted.
  16. Subject's CT scan indicates the presence of any the following radiologic abnormalities:

    1. Pulmonary nodule on CT scan greater than 0.8 cm in diameter (Does not apply if present for one (1) year or more without increase in size or if proven benign by ).
    2. Radiologic picture consistent with active pulmonary infection, e.g., unexplained parenchymal infiltrate.
    3. Significant interstitial lung disease.
    4. Significant pleural disease.
  17. Subject's baseline indicates non-atrial arrhythmias or conduction abnormalities.
  18. Subject has high cardiac risk after undergoing cardiac risk assessment in accordance with published guidelines or ischemic heart disease, congestive heart failure, renal failure, or cerebrovascular disease.
  19. Subject has asthma (reversible airway obstruction), chronic bronchitis, or bronchiectasis.
  20. Subject has allergy or sensitivity to medications required to safely perform bronchoscopy under conscious sedation or general anesthesia.
  21. Subject participated in an study of a drug, biologic, or device not currently approved for marketing within 30 days prior to Screening visit. Subjects being followed as part of a long-term surveillance of a non-pulmonary study that has reached its primary endpoint are eligible for participation in this study.
  22. Subject has (BMI) \< 18 kg/m2 or > 35 kg/m2.
  23. Subject is a female who is pregnant, breast-feeding, or planning to be pregnant in next 12 months.
  24. Subject has clinically significant abnormal screening laboratory test results per the Institution specific reference laboratory normal values for the following:

    1. White blood cells (total)
    2. Hematocrit
    3. or INR
    4. Partial thromboplastin time
    5. Positive β-HCG Pregnancy test (if female)
  25. Subject has evidence of severe disease which in the judgment of the Investigator may compromise survival for the duration of the study (at least 12 months) e.g.:

    1. /AIDs
    2. Active
    3. Stroke or (TIA) within 12 months of Screening visit
    4. Myocardial infarction within six (6) months of the Screening visit
    5. Congestive heart failure within six (6) months of the Screening visit defined as clinical evidence of right or left heart failure or \< 45% on echocardiogram
  26. Subject has uncontrolled diabetes mellitus.
  27. Subject has any other condition that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the subject including but not limited to alcoholism, high risk for drug abuse, or noncompliance in returning for follow-up visits.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Other
    AeriSeal and Zephyr Valve Treatment

    Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-). Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR).

    Device: AeriSeal · Device: Zephyr Valves

Interventions

  • DeviceAeriSeal

    The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.

  • DeviceZephyr Valves

    The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.

    Also known as: Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System

06

What researchers measure

Primary outcomes

  1. Percentage of subjects converted from a positive collateral ventilation status (CV+) to having little to no collateral ventilation (CV-) in the treated lobe.

    The primary AeriSeal endpoint will be the percentage of study subjects that are successfully converted from a positive collateral ventilation status (CV+) in the treated lobe to having little to no collateral ventilation (CV-) in the treated lobe six (6) weeks after delivery of AeriSeal.

    Time frame: 6-weeks post-AeriSeal treatment

  2. Treated Lobe Volume Reduction (TLVR) responders

    The primary Zephyr Valve endpoint is the percentage of subjects achieving TLVR ≥ 350 mL (TLVR Responders) at 45-days post-valve treatment. That is, the percentage of CV+ to CV- converted subjects from Stage 1 who subsequently receive valves and have Treated Lobe Volume Reduction (TLVR) of ≥ 350 mL, via High-resolution computed tomography (HRCT) at 45-days post-valve treatment.

    Time frame: 45-days post-Zephyr Valve treatment

Secondary outcomes

  1. Forced Expiratory Volume in 1 second (FEV1)

    Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1) change from Baseline to 3-months (Absolute and Percent changes)

    Time frame: 3-months

  2. Residual volume (RV)

    Residual volume (RV) change from Baseline to 3-months (Absolute and Percent changes).

    Time frame: 3-months

Other outcomes

  1. Forced Expiratory Volume in 1 second (FEV1)

    Post-Bronchodilator Forced Expiratory Volume in 1 second (FEV1) change from Baseline to 6-months and 12-months (Absolute and Percent changes)

    Time frame: 6-months and 12-months

  2. Residual volume (RV)

    Residual volume (RV) change from Baseline to 6-months and 12-months (Absolute and Percent changes).

    Time frame: 6-months and 12-months

  3. Six-Minute Walk Distance (6MWD)

    Change in Six-Minute Walk Distance (6MWD) from Baseline to 3-months, 6-months, and 12-months.

    Time frame: 3-months, 6-months, and 12-months

  4. St. George's Respiratory Questionnaire (SGRQ) Total Score

    Change in St. George's Respiratory Questionnaire (SGRQ) Total Score from Baseline to 3-months, 6-months, and 12-months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: 3-months, 6-months, and 12-months

  5. Modified Medical Research Council Dyspnea Score (mMRC)

    Change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 3-months, 6-months, and 12-months. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.

    Time frame: 3-months, 6-months, and 12-months

  6. Total Lung Capacity (TLC)

    Changes in TLC from Baseline to 3-months, 6-months, and 12-months (Absolute and Percent changes).

    Time frame: 3-months, 6-months, and 12-months

  7. Inspiratory Capacity (IC)

    Changes in IC from Baseline to 3-months, 6-months, and 12-months (Absolute and Percent changes).

    Time frame: 3-months, 6-months, and 12-months

  8. Residual Volume/Total Lung Capacity (RV/TLC) ratio

    Changes in the RV/TLC ratio from Baseline to 3-months, 6-months, and 12-months (Absolute and Percent changes).

    Time frame: 3-months, 6-months, and 12-months

  9. Inspiratory Capacity/Total Lung Capacity (IC/TLC) ratio

    Changes in the IC/TLC ratio from Baseline to 3-months, 6-months, and 12-months (Absolute and Percent changes).

    Time frame: 3-months, 6-months, and 12-months

  10. Treated Lobe Volume Reduction (TLVR)

    Changes in TLVR from Baseline to 6-months and 12-months.

    Time frame: 6-months and 12-months

07

Study locations

14 sites
  • The Wesley Hospital
    Brisbane, Australia
  • Macquarie University Hospital
    Sydney, Australia
  • CHU Limoges
    Limoges, 87042, France
  • CHU Toulouse
    Toulouse, 31059, France
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Ruhrlandklinik Essen
    Essen, 45239, Germany
  • ThoraxKlinik
    Heidelberg, 69126, Germany
  • ASST Spedali Civili, University Hospital
    Brescia, 25123, Italy
  • University Medical Center Groningen
    Groningen, 9700 RB, Netherlands
  • University Hospital of Zurich
    Zurich, Rämistrasse 100 8006, Switzerland
  • Golden Jublilee National Hospital
    Clydebank, Scotland G81 4DY, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • Nottingham University Hospitals
    Nottingham, NG5 1PB, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2023, 34 months.

Of 60 interventional studies with no phase under Emphysema, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 22, 2020
StartActual
Dec 15, 2020
Primary completionActual
Oct 24, 2023
CompletionActual
Oct 21, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04559464
Lead sponsor
Pulmonx Corporation
Responsible party
Sponsor
First posted
Sep 22, 2020
Start date
Dec 15, 2020
Primary completion
Oct 24, 2023
Completion
Oct 21, 2024
Last update
Nov 4, 2024

Study contacts

Joshua Percy
study director · Pulmonx Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion